laboratori corp america hldg
look solid growth thesi
despit view anoth solid quarter labcorp start see
theme earn result need clean order reward
market convers investor today labcorp topic du
jour softer quarterli book-to-bil covanc estim covanc post
book-to-bil quarter view timing-rel
context new expand strateg relationship announc quarter
broadli covanc post mid-to-high singl digit organ growth ttm
book-to-bil look healthi addit
encourag labcorp progress integr diagnost data better patient
engag tool cro offer demonstr enterpris strategi final
covanc post solid margin expans highlight launchpad
initi bear fruit solid result labcorp diagnost relief
softer-than-expect result quest yesterday labcorp dx post growth
y/i came estim vs equival growth quest
repres miss capit deploy pleas see
labcorp repurchas anoth million share overal combin
perform lab cro busi continu give us convict
labcorp enterpris strategi view great valu price-to-earnings
action modestli lower forecast labcorp emb slightli
conservat relat net impact open unitedhealth
aetna payor contract describ observ continu believ
net-net share shift two contract modest headwind labcorp
forecast ep growth y/i vs prior
forecast growth y/i cours think simpli look net-net
contract labcorp quest myopic context larger
share opportun payor network open increment margin
think investor free call option current level potenti upsid
baselin payor network benefit design chang drive share toward nation
lab final labcorp meaning cash firepow deploy drive
earn upsid reiter overweight rate labcorp top pick
lh quarterli annual ep usd
return equiti ttm
link barclay live interact chart
barclay research consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay laboratori corp america hldg
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay laboratori corp america hldg
despit view anoth solid quarter labcorp start see theme
earn result need clean order reward market
convers investor today labcorp topic du jour softer
quarterli book-to-bil covanc estim covanc post book-to-bil
quarter view timing-rel context new
expand strateg relationship announc quarter broadli covanc post
mid-to-high singl digit organ growth ttm book-to-bil
look healthi also encourag labcorp progress integr
diagnost data better patient engag tool cro offer demonstr
compani enterpris strategi final covanc post solid margin expans
highlight launchpad initi bear fruit solid result labcorp
diagnost relief softer-than-expect result quest yesterday labcorp
dx post growth y/i came estim vs equival
growth quest repres miss capit deploy pleas
see labcorp repurchas anoth million share overal combin
perform lab cro busi continu give us convict labcorp
enterpris strategi view great valu price-to-earnings
modestli lower forecast labcorp emb slightli
conservat relat net impact open aetna
payor contract describ observ continu believ net-net share
shift two contract modest headwind labcorp
forecast ep repres growth y/i vs prior forecast
repres growth y/i cours think simpli look
net-net contract labcorp quest myopic context larger
share opportun payor network open histor nation exclus lab
agreement allow hospit region lab thrive detriment nation lab
increment margin think investor free call option current level
baselin potenti upsid payor network benefit design chang drive
share toward nation lab final highlight labcorp meaning cash
firepow deploy leverag ebitda expect gener
free cash year end proce food solut
sale eurofin lot flexibl drive earn upsid reiter
overweight rate labcorp also top pick price target
repres adj ep ebitda
labcorp adjust revenu account higher reimburs revenu well
previous announc food solut sale narrow expect core
ep labcorp expect revenu growth narrow either end
previou guidanc covanc constant currenc growth expect
rang midpoint also includ
chiltern acquisit believ add growth impli
organ growth guidanc mid-to-high singl digit unchang fx
tailwind total growth expect y/i labcorp diagnost expect show
total growth vs previous constant currenc growth vs
previous labcorp note lower due food solut sale
detail pleas see report lh brief thought food solut sale
barclay laboratori corp america hldg
ep guidanc repres growth y/i narrow
either end rang remind ep forecast includ benefit
tax reform assum tax rate ad growth y/i
labcorp size expect impact pama headwind continu expect
free cash flow rang billion
pleas see report
risk/reward new payor
paradigm upgrad ow
continu see renew end exclus contract nation
payer real strateg posit nation lab labcorp quest
remind labcorp quest recent announc new contract
aetna view game-chang industri previous labcorp quest
exclus relationship aetna respect
open januari overal believ new contract help break
barrier nation lab consolid share test improv patient
experi payor
think could big deal share save prefer lab
volum shift high-cost set first lab industri volum
shift high-cost provid toward prefer network plan
develop pool save share provid instead
commodit lab lab result qualiti metric differenti
particip price tool incentiv effici deliveri care encourag
util prefer network also consid put place
econom incent patient physician adher network would
also first histori lab industri would includ waiv out-of-pocket
guidanc dx dx dx organ organ growth barclay laboratori corp america hldg
cost patient co-pay deduct encourag adopt given rapid
growth high-deduct health plan past decad believ could drive
strong incent patient better direct shift volum
continu think share dynam labcorp quest vs rest
industri far materi relev share dynam two
nation lab said obvious share shift quest
labcorp aetna contract open believ
net yield modest benefit quest modest headwind labcorp
simpl math larger aetna suggest quest would net
beneficiari vice versa labcorp said fact labcorp earn price
increas critic element deal calculu also
cement truli paradigm shift industri base case analysi assum
would around ebitda tailwind quest around ebitda
headwind labcorp
base case estim potenti price/mix chang labcorp
payor enu shift mmlabcorpquesttot labstot totalunitedhealth chang chang aet aet shift mmlabcorpquesttot labstot totaltot aet chang payor payor compani impact mmlabcorpquesttot ebitda compani ebitda barclay laboratori corp america hldg
clearli much bigger opportun labcorp quest test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient clear
nation payor recogn need work nation lab better drive
valu system old contract allow region lab better penetr physician
offic could arbitrag benefit fact nation lab out-
of-network one nation payor drove higher price nation payor
overal higher out-of-pocket cost patient quest believ old payor
paradigm drove complex physician would field question
patient around unexpect lab cost back in-network remov unnecessari
barrier compet nation lab believ share could move quickli
commerci execut get messag number
get larg quickli current valuat believ investor free call option
potenti consolid upsid outsid hospit lab opportun size
around billion nation lab repres share
consolid test major theme coverag past year
believ see earli signal result acceler quest
labcorp quest post lab growth includ organ
acquir growth quest best growth sinc labcorp post
total lab growth includ organ acquir growth
labcorp best growth sinc sinc averag revenu growth lab
highlight recent acceler growth consolid
total revenu growth lab busi
organ revenu growth lab busi
volum quarter increas includ organ growth
 weather calendar impact volum quarter
impli underli util increas y/i repres deceler
q/q though consist trend labcorp post y/i declin
rev-per-req attribut pama well acquisit mix wind
includ roughli tailwind fx price neg impact pama
acquisit text mix one exampl recent mix headwind ceo
dave king call growth headwind revenu per requisit
barclay laboratori corp america hldg
note organ reimburs growth adjust fx beacon lb
labcorp adjust mix
covanc revenu came slightli expect total growth
detail around organ growth certainli gotten less transpar sinc
implement think done disservic cro industri
investor labcorp comment covanc deliv mid-to-high singl digit organ
growth quarter look consist result pencil adjust
time reimburs pass-through encourag sequenti
improv organ growth estim improv compani
optimist around covanc competit market guid toward
organ growth mid- high-singl digit
per req dgxlh millionsestestestestfisc year end dec lab lab growth acquir total access organ net new weather calendar underli ppa beacon organ lab medicar pama overal y/i organ growth barclay laboratori corp america hldg
addit covanc post ttm book-to-bil remind
compani annual impact cancel two larg clinic studi
manag continu enthusiast around integr offer
elabor success compani area clinic trial recruit
joint analyt companion diagnost develop commerci
compani note covanc integr offer key attract new
custom far compani accru billion award data
primari reason win
segment organ growth labcorp
labcorp activ new acquisit partnership divestitur
impact pace growth throughout recent partnership mount
sinai appalachian region healthcar continu momentum start
organ growth modest compani done effect job win new
busi hospit partnership acquisit continu believ effort
provid better healthcar integr patient cost share greater regul fda
ldt reimburs pressur pama driver share consolid toward
effici provid labcorp quest
organ growth labcorp dxcovanc drug develop barclay laboratori corp america hldg
us market continu fragment share repres
two independ market leader believ reimburs pressur drive lab
consolid smaller competitor lack scale drive effici
busi margin come increas pressur labcorp kick deal activ
acquisit mt sinai outreach oper follow sizabl paml
acquisit ad million refer lab test busi affili
provid system cathol initi quest activ year
acquisit announc total eight deal headlin million
acquisition/partnership peacehealth million acquisit
medfusion/clearpoint texa final sonic gotten action two jv
nyu nyc western connecticut network deal activ easili
eclips million lab industri revenu aggreg us
industri revenu look chart clear pace
partnership acquisit pick
affili lab barclay laboratori corp america hldg
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ partial attribut pama
uncertainti major driver thesi industri updat
reimburs laboratori test went effect januari clearli
mind industri particip hospit laboratori view non-cor part
health system ideal area hospit gener save strike deal
labcorp quest allow hospit focu core busi continu
provid patient access qualiti laboratori servic mani hospit system alreadi
financi pressur pama repres
drive
manag team chang decision-mak
increment risk
march labcorp announc multi-year partnership appalachian
region healthcar labcorp provid technic servic appalachian region
healthcar hospital-bas lab refer test servic entir network
facil clinician labcorp also grant appalachian region healthcar access
enhanc inform technolog data analyt help improv deliveri
patient care appalachian region healthcar oper hospit kentucki
januari labcorp announc acquir clinic outreach
lab asset mount sinai health system nyc believ highlight
compani focu busi develop health system also repres
nice tuck-in acquisit compani system give labcorp access serv
anchor health system nyc market offer clinic patholog test
includ cytolog relat mdx test addit labcorp oper
mount sinai patient servic center psc region ad exist local
network psc opportun could includ collabor clinic trial
strengthen resourc covanc well work companion diagnost
medic educ term size estim transact could add
top line growth run-rat basi
februari labcorp announc agreement acquir patholog
associ medic laboratori paml mark largest laboratori acquisit
notabl deal labcorp paml larg hospital-own laboratori
provid refer outreach test servic hospit partner asset
own jv provid servic provid cathol
yeardealslabtarget/partnerdatetyp sinai region laboratori associ outreach clinic outreach medic laboratori jvquestcap cod care outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut network venturequestmontefior serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford outreach acquisit barclay laboratori corp america hldg
pleas see report
initi chi two largest hospit system countri addit paml
labcorp also plan acquir lab interest number joint ventur
believ would ultim lead complet ownership busi announc
transact valid labcorp commit expand partnership
anchor hospit system come close heel acquisit mt
sinai outreach busi term disclos news report
suggest paml million revenu estim could add
revenu growth annual basi lab growth
acquisit expand labcorp presenc pacif northwest mid-west south
give compani access serv two largest health system
implement medicar clinic lab fee schedul kick
largest chang diagnost reimburs year result support
view pama lead meaning medicar cut time lead
period heighten lab industri consolid labcorp size pama expect
headwind revenu growth headwind ep remind
price reduct drop earn outsiz
impact ep growth y/i financi impact still meaning yet manag
given medicar clf repres labcorp diagnost revenu
total medicar reimburs chang actual sizabl survey work
interact lab director suggest industri experi period meaning
consolid ultim believ smaller lab outsiz medicar exposur
consolid time either organ inorgan benefit labcorp quest
industri leader
quot headlin medicar cut clf time roughli
code see rate decreas vs rate increas code
rate reduct greater labcorp quest estim around
top code see rate reduct annual first year reduct
increasingli sever routin test estim top
hcpc code clf spend cut altogeth top code
contribut clf spend almost million claim
design top code gener billion clf payment
top code cut genom health oncotyp dx top code
increas top code cut impli
medicar reimburs payment still weight median
averag addit anoth three test cut display magnitud
futur cut top code includ lipid panel reduct
code contribut nearli clf spend code drug
test def class new volum weight median pama reduct
overal continu believ signific rate reduct routin code
lead increas outsourc effici provid labcorp quest
barclay laboratori corp america hldg
top hcpc code clf spend
pleas see report
takeaway clfs/pama
propos
potenti off-set horizon propos physician
fee schedul announc seek public comment definit chang
applic lab could broaden scope lab survey next pama data
reimburs depend number addit hospit outreach lab
survey report period clear chang view
expect medicar rate cut pama rate lock
data report period remind data report take place everi
year said think market may view posit given potenti
rate increas relief futur cut current model addit cut
histor defin applic lab base lab nation provid identifi
npi whether medicar revenu gener npi
clf hospit lab npi sit parent hospit level given
hospit gener major revenu ipp opp fee schedul vs
clf npi applic lab definit exclud mani hospit lab data
collect period vast major data submit pama data
collect period labcorp quest seek comment
whether use file bill type clia certif number
would recommend read brief section page propos
describ merit drawback use clia certif number
agenc chose use past lab industri histor lobbi
use clia number would put focu back lab report entiti
possibl major hospit lab medicar revenu clf
caveat clia number may repres entir hospit lab rather
outreach lab ipps/opp payment may larger clf revenu
hcpc codehcpc code descriptiontot claim linestot payment total nlaweight median payment w/ payment w/ payment w/ thyroid stim metabol cbc w/auto diff hemoglobin test def panel total test def parathormon psa free culture/coloni test def test def natriuret colorect breast cbc folic acid suscept barclay laboratori corp america hldg
broader inclus hospit outreach lab could lead increas medicar
reimburs base volum weight median rate submiss
labcorp quest undoubtedli still domin data collect period
inclus higher cost lab could lift higher wherev volum weight median lie
labcorp report revenu billion forecast driven
acquir growth off-set modestli lower organ growth fx
labcorp dx revenu billion includ organ growth coupl
acquir growth fx tailwind drive overal growth y/i
came forecast volum growth came
estim organ volum solid y/i
forecast stand contrast weaker organ volum
growth quest tuesday mark continu improv
y/i labcorp organ revenu growth
histor stronger peer continu acquisit ad
volum growth estim revenu per requisit
decreas y/i lower forecast keep mind pama
headwind within rev-per-req mix drive chang
covanc revenu billion estim
revenu increas y/i constant currenc growth adjust
fx ttm book-to-bil
compar
compani note press releas compani
activ win expand strateg partnership contribut
futur studi award may quarterli variabl award
quarterli revenu million organ growth
adjust oper margin increas covanc declin labcorp
diagnost segment adjust ebit ex-amort grew y/i million
adj ebit margin percentag net revenu declin y/i
estim labcorp diagnost margin declin y/i
covanc drug develop margin
improv labcorp diagnost segment margin project launchpad
growth y/i barclay laboratori corp america hldg
acquisit stronger revenu off-set neg impact pama
covanc saw benefit covanc launchpad program top-lin growth
chiltern acquisit remind labcorp gener million save
expans launchpad includ covanc labcorp remain
track gener million save expans launchpad includ
covanc well million cost synergi integr chiltern
end
adj ebit margin segment ex-corpor overhead
sg repres net revenu quarter in-lin expect
import note due account chang cost revenu
optic increas percentag revenu sg expens decreas
percentag revenu
sg trend revenu
revenu higher expect ebitda
margin came expect due lower gross margin
sg abad debt lab barclay laboratori corp america hldg
margin trend revenu
flow oper came million modestli estim
million cffo repres adjust net incom quarter capital-expenditure
million repres net revenu y/i capit
deploy consist million share repurchas labcorp deploy
billion toward chiltern paml mt sinai outreach toward share
labcorp continu gener signific free cash flow believ flexibl
even chiltern activ capit deploy market
compani continu expect gener free cash flow rang billion
billion compani also gener proce
food solut sale eurofin labcorp exit net debt ebitda
use oper million
marginsebit flowcapex barclay laboratori corp america hldg
labcorp mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay laboratori corp america hldg
million except per share dataestestestestestestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
labcorp statement flow
estestestestestestestestestest loss sale interest zero coupon earn excess incom expens expens chang work y/i adj net sale payment paid invest revolv credit term vendor-financ debt issuanc payment interest interest tax benefit stock proce issuanc common per growth y/ynet financ exchang increase/decreas begin end adj net debt ttm barclay laboratori corp america hldg
receiv expens incom equip equiti equityaccount payabl expens coupon-subordin credit incom portion credit coupon-subordin senior senior less current leas incom sharehold liabilit barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
